Managing particulates in cellular therapy

Dominic Clarke, Dorit Harati, Jerold Martin, Jon Rowley, Juergen Keller, Michael McCaman, Miguel Carrion, Ohad Karnieli, Richard Maziarz, Robert Perry, Steve Oh, Jean Stanton

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

The concept of particulates, while common to many in the pharmaceutical and blood transfusion disciplines, represents a distinct challenge in the field of cellular therapy. With newly discovered products advancing through clinical trials, the focus has shifted to ensuring products are manufactured in a reliable and safe manner. Given the unique manufacturing processes and resulting products (i.e. the cell being the active ingredient of the product), the way in which particulates are viewed and subsequently tested needs to be reviewed. No specific test or method for particulates will apply to all products, and guidance documents will be generated over time as more cell therapy products are approved. The details of the processes, testing methods used and acceptance criteria established for particulates will play a major role in generating the guidance documents. This will ultimately allow for the manufacture and administration of safe and effective products without thwarting advancement of the cellular therapy field. The intent of this review is to bring awareness to the topic of particulates with respect to cell therapy, and encourage a more open dialog and exchange of examples within the industry. We have reviewed the concept of particulates, where they originate and how they are introduced to cell therapy products, and the current methods available for their detection. We have also reviewed the relevance of current guidance documents and present potential strategies to move forward and address and control unwanted contaminating particulates in cell therapy products.

Original languageEnglish (US)
Pages (from-to)1032-1040
Number of pages9
JournalCytotherapy
Volume14
Issue number9
DOIs
StatePublished - Oct 2012

Fingerprint

Cell- and Tissue-Based Therapy
Therapeutics
Blood Transfusion
Industry
Clinical Trials
Pharmaceutical Preparations

Keywords

  • Cellular therapy
  • Disposable
  • Injectable
  • Parenteral
  • Particulate

ASJC Scopus subject areas

  • Immunology
  • Immunology and Allergy
  • Molecular Medicine

Cite this

Clarke, D., Harati, D., Martin, J., Rowley, J., Keller, J., McCaman, M., ... Stanton, J. (2012). Managing particulates in cellular therapy. Cytotherapy, 14(9), 1032-1040. https://doi.org/10.3109/14653249.2012.706709

Managing particulates in cellular therapy. / Clarke, Dominic; Harati, Dorit; Martin, Jerold; Rowley, Jon; Keller, Juergen; McCaman, Michael; Carrion, Miguel; Karnieli, Ohad; Maziarz, Richard; Perry, Robert; Oh, Steve; Stanton, Jean.

In: Cytotherapy, Vol. 14, No. 9, 10.2012, p. 1032-1040.

Research output: Contribution to journalArticle

Clarke, D, Harati, D, Martin, J, Rowley, J, Keller, J, McCaman, M, Carrion, M, Karnieli, O, Maziarz, R, Perry, R, Oh, S & Stanton, J 2012, 'Managing particulates in cellular therapy', Cytotherapy, vol. 14, no. 9, pp. 1032-1040. https://doi.org/10.3109/14653249.2012.706709
Clarke D, Harati D, Martin J, Rowley J, Keller J, McCaman M et al. Managing particulates in cellular therapy. Cytotherapy. 2012 Oct;14(9):1032-1040. https://doi.org/10.3109/14653249.2012.706709
Clarke, Dominic ; Harati, Dorit ; Martin, Jerold ; Rowley, Jon ; Keller, Juergen ; McCaman, Michael ; Carrion, Miguel ; Karnieli, Ohad ; Maziarz, Richard ; Perry, Robert ; Oh, Steve ; Stanton, Jean. / Managing particulates in cellular therapy. In: Cytotherapy. 2012 ; Vol. 14, No. 9. pp. 1032-1040.
@article{e7d51ed8a8a649e78c423283b12d716e,
title = "Managing particulates in cellular therapy",
abstract = "The concept of particulates, while common to many in the pharmaceutical and blood transfusion disciplines, represents a distinct challenge in the field of cellular therapy. With newly discovered products advancing through clinical trials, the focus has shifted to ensuring products are manufactured in a reliable and safe manner. Given the unique manufacturing processes and resulting products (i.e. the cell being the active ingredient of the product), the way in which particulates are viewed and subsequently tested needs to be reviewed. No specific test or method for particulates will apply to all products, and guidance documents will be generated over time as more cell therapy products are approved. The details of the processes, testing methods used and acceptance criteria established for particulates will play a major role in generating the guidance documents. This will ultimately allow for the manufacture and administration of safe and effective products without thwarting advancement of the cellular therapy field. The intent of this review is to bring awareness to the topic of particulates with respect to cell therapy, and encourage a more open dialog and exchange of examples within the industry. We have reviewed the concept of particulates, where they originate and how they are introduced to cell therapy products, and the current methods available for their detection. We have also reviewed the relevance of current guidance documents and present potential strategies to move forward and address and control unwanted contaminating particulates in cell therapy products.",
keywords = "Cellular therapy, Disposable, Injectable, Parenteral, Particulate",
author = "Dominic Clarke and Dorit Harati and Jerold Martin and Jon Rowley and Juergen Keller and Michael McCaman and Miguel Carrion and Ohad Karnieli and Richard Maziarz and Robert Perry and Steve Oh and Jean Stanton",
year = "2012",
month = "10",
doi = "10.3109/14653249.2012.706709",
language = "English (US)",
volume = "14",
pages = "1032--1040",
journal = "Cytotherapy",
issn = "1465-3249",
publisher = "Informa Healthcare",
number = "9",

}

TY - JOUR

T1 - Managing particulates in cellular therapy

AU - Clarke, Dominic

AU - Harati, Dorit

AU - Martin, Jerold

AU - Rowley, Jon

AU - Keller, Juergen

AU - McCaman, Michael

AU - Carrion, Miguel

AU - Karnieli, Ohad

AU - Maziarz, Richard

AU - Perry, Robert

AU - Oh, Steve

AU - Stanton, Jean

PY - 2012/10

Y1 - 2012/10

N2 - The concept of particulates, while common to many in the pharmaceutical and blood transfusion disciplines, represents a distinct challenge in the field of cellular therapy. With newly discovered products advancing through clinical trials, the focus has shifted to ensuring products are manufactured in a reliable and safe manner. Given the unique manufacturing processes and resulting products (i.e. the cell being the active ingredient of the product), the way in which particulates are viewed and subsequently tested needs to be reviewed. No specific test or method for particulates will apply to all products, and guidance documents will be generated over time as more cell therapy products are approved. The details of the processes, testing methods used and acceptance criteria established for particulates will play a major role in generating the guidance documents. This will ultimately allow for the manufacture and administration of safe and effective products without thwarting advancement of the cellular therapy field. The intent of this review is to bring awareness to the topic of particulates with respect to cell therapy, and encourage a more open dialog and exchange of examples within the industry. We have reviewed the concept of particulates, where they originate and how they are introduced to cell therapy products, and the current methods available for their detection. We have also reviewed the relevance of current guidance documents and present potential strategies to move forward and address and control unwanted contaminating particulates in cell therapy products.

AB - The concept of particulates, while common to many in the pharmaceutical and blood transfusion disciplines, represents a distinct challenge in the field of cellular therapy. With newly discovered products advancing through clinical trials, the focus has shifted to ensuring products are manufactured in a reliable and safe manner. Given the unique manufacturing processes and resulting products (i.e. the cell being the active ingredient of the product), the way in which particulates are viewed and subsequently tested needs to be reviewed. No specific test or method for particulates will apply to all products, and guidance documents will be generated over time as more cell therapy products are approved. The details of the processes, testing methods used and acceptance criteria established for particulates will play a major role in generating the guidance documents. This will ultimately allow for the manufacture and administration of safe and effective products without thwarting advancement of the cellular therapy field. The intent of this review is to bring awareness to the topic of particulates with respect to cell therapy, and encourage a more open dialog and exchange of examples within the industry. We have reviewed the concept of particulates, where they originate and how they are introduced to cell therapy products, and the current methods available for their detection. We have also reviewed the relevance of current guidance documents and present potential strategies to move forward and address and control unwanted contaminating particulates in cell therapy products.

KW - Cellular therapy

KW - Disposable

KW - Injectable

KW - Parenteral

KW - Particulate

UR - http://www.scopus.com/inward/record.url?scp=84866517094&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84866517094&partnerID=8YFLogxK

U2 - 10.3109/14653249.2012.706709

DO - 10.3109/14653249.2012.706709

M3 - Article

VL - 14

SP - 1032

EP - 1040

JO - Cytotherapy

JF - Cytotherapy

SN - 1465-3249

IS - 9

ER -